FDMT - 4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm
2024-02-06 08:00:00 ET
Summary
- 4D Molecular Therapeutics' gene therapy, 4D-150, shows potential to reduce the treatment burden for patients with severe wet AMD.
- Interim findings from a Phase 2 trial demonstrate up to an 89% reduction in yearly anti-VEGF injections with 4D-150.
- FDMT plans to initiate a Phase 3 trial in wet AMD in Q1 2025, positioning 4D-150 as a promising candidate in the treatment landscape.
4D Molecular's Gene Therapy Promises Reduced Treatment Burden for Wet AMD
4D Molecular Therapeutics (FDMT) is up over 80% today after it announced Phase 2 PRISM data in patients with severe wet AMD. Below, I take a closer look at the data and what it means for patients and investors....
4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm